Get started
Author

Romana Mikyšková

Observed names: Mikyskova, Romana, R Mikyskova, R Mikysková, R Mikyšková, R. Mikyskova, R. Mikysková, R. Mikyšková, ROMANA MIKYŠKOVÁ, Romana Mikyskova, Romana Mikysková
ORCID: 0000-0002-6857-1155
Observed ORCID: 0000-0002-6857-1155
OpenAlex ID: A5010063233
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients
2019 · Iva Truxova, Lenka Kasikova, et al. · Haematologica · 55
PDF
Cyclophosphamide-induced Myeloid-derived Suppressor Cell Population Is Immunosuppressive But Not Identical to Myeloid-derived Suppressor Cells Induced By Growing TC-1 Tumors
2012 · Romana Mikyšková, Marie Indrová, et al. · Journal of Immunotherapy · 52
DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment
2014 · Romana Mikyšková, Marie Indrová, et al. · Journal of Leukocyte Biology · 51
PDF
Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status
2011 · J Šímová, V Polláková, et al. · British Journal of Cancer · 47
PDF
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF
2004 · Romana Mikysková, Marie Indrová, et al. · International Journal of Oncology · 41
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy
2015 · ROMANA MIKYŠKOVÁ, IVAN ŠTĚPÁNEK, et al. · International Journal of Oncology · 33
PDF
Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients
2023 · Peter Holicek, Iva Truxova, et al. · Cell Death and Disease · 30
PDF
Chronic inflammation decreases HSC fitness by activating the druggable Jak/Stat3 signaling pathway
2022 · Srdjan Grusanovic, Petr Danek, et al. · EMBO Reports · 23
PDF
Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics
2022 · Zofia Chrienova, David Rysanek, et al. · Frontiers in Aging Neuroscience · 22
Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy
2005 · Romana Mikysková, Jan Bubeník, et al. · International Journal of Oncology · 22
Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines
2016 · Jana Simova, Olena Sapega, et al. · Oncotarget · 21
PDF
STAT3 inhibitor Stattic and its analogues inhibit STAT3 phosphorylation and modulate cytokine secretion in senescent tumour cells
2023 · Romana Mikyskova, Olena Sapeg, et al. · Molecular Medicine Reports · 20
PDF
Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours
2003 · L. Mendoza, J. Bubeník, et al. · International Journal of Oncology · 17
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice
2017 · Romana Mikyskova, Marie Indrova, et al. · OncoImmunology · 16
PDF
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
2003 · Marie Indrová, Jan Bubeník, et al. · PubMed · 16
Avenue to X-ray-induced photodynamic therapy of prostatic carcinoma with octahedral molybdenum cluster nanoparticles
2022 · Martina Koncošová, Michaela Rumlová, et al. · Journal of Materials Chemistry B · 14
Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin
2002 · M. Indrova, J. Bubenik, et al. · International Journal of Oncology · 11
Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases
2000 · Romana Mikyšková, Jan Bubeník, et al. · Clinical & Experimental Metastasis · 11
Therapy for minimal residual tumor disease: β‐Galactosylceramide inhibits the growth of recurrent HPV16‐associated neoplasms after surgery and chemotherapy
2009 · Jana Šímová, Marie Indrová, et al. · International Journal of Cancer · 10
PDF
Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v
2025 · Hana Matuskova, Pavel Marasek, et al. · Journal for ImmunoTherapy of Cancer · 9
HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
2004 · Milan Reinis, Marie Indrová, et al. · International Journal of Oncology · 8
Adjuvant Cytokine Treatment of Minimal Residual Disease after Surgical Therapy in Mice Carrying HPV16-Associated Tumours: Cytolytic Activity of Spleen Cells from Tumour Regressors
2003 · Marie Indrová, R. Mikyšková, et al. · Folia Biologica · 8
PDF
Tumour-Inhibitory Effects of Dendritic Cells Administered at the Site of HPV 16-Induced Neoplasms
2002 · Luis Mendoza, J. Bubeník, et al. · Folia Biologica · 7
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
2025 · Stephane Champiat, Elena Garralda, et al. · Cell Reports Medicine · 6
Discovery of a 6-Aminobenzo[b]thiophene 1,1-Dioxide Derivative (K2071) with a Signal Transducer and Activator of Transcription 3 Inhibitory, Antimitotic, and Senotherapeutic Activities
2024 · Patrik Oleksak, David Rysanek, et al. · ACS Pharmacology & Translational Science · 6
PDF
Works count: 51
Citation count: 590
H-index: 15
I10-index: 19
Year
Topic
Type